50 likes | 56 Views
The report "Biosurgery Market by Product Type (Sealants, Hemostats, Adhesion Barrier, Soft Tissue Attachments, Biological Meshes, DBM, Bone Graft Substitutes), Application (Orthopedic, Cardiovascular), End User (Hospitals, Clinics) - Global Forecast to 2026", is projected to reach USD 16.0 billion by 2026 from USD 12.2 billion in 2021, at a CAGR of 5.7%
E N D
Biosurgery Market At a CAGR of 5.7%
The report "Biosurgery Market by Product Type (Sealants, Hemostats, Adhesion Barrier, Soft Tissue Attachments, Biological Meshes, DBM, Bone Graft Substitutes), Application (Orthopedic, Cardiovascular), End User (Hospitals, Clinics) - Global Forecast to 2026", is projected to reach USD 16.0 billion by 2026 from USD 12.2 billion in 2021, at a CAGR of 5.7% during the forecast period. The prominent players in this market are Johnson & Johnson (US), Baxter International Inc. (US), Medtronic Plc (Ireland), Becton, Dickinson & Co. (US), B. Braun Melsungen AG (Germany), Stryker Corp. (US), Integra Lifesciences Holdings Corp. (US), CSL Ltd. (Australia), Hemostasis LLC. (US), Pfizer Inc. (US), Cyrolife Inc. (US), Zimmer Biomet (US), Kuros Biosciences AG (Switzerland), Orthofix Medical Inc. (US), and Smiths & Nephew Plc. (UK).
Johnson & Johnson (US) held the leading position in the biosurgery market in 2020. The company offers a wide range of biosurgery products including bone graft substitutes, soft tissue attachments, hemostats, staple line reinforcement agents, and surgical sealants and adhesives. The company has a strong geographic presence established through its manufacturing and distribution facilities, across the globe. The company leverages its research capabilities and innovative product portfolio to ensure a leading position in the biosurgery market. In FY2020, company invested about USD 12.2 Billion in R&D, out of which about USD 2.1 billion were invested in Medical Devices business segment, an increase of 9.8% in comparison to FY2019. Medtronic Plc (Ireland) held the second position in the global biosurgery market. Company has exhaustive product portfolio, specifically in bone graft substitutes and soft tissue attachment category. Additionally, the company leverages its research capabilities and innovative product portfolio to ensure a leading position in the biosurgery market. In FY2020, the company invested USD 2,331 million in R&D, up from USD 2253 million in FY2018. Medtronic focuses on organic growth strategies such as innovation, product launch and approval for its growth in the biosurgery market, as evidenced by its recent product approval and launches during FY2018 to FY2019 across orthopedic and spine surgery portfolio.
The surgical sealants and adhesives segment is expected to grow at the highest CAGR The orthopedic segment accounted for the largest share Hospitals segment accounted for the largest share Asia Pacific is expected to show the highest growth rate
Facebook MarketsandMarkets™ INC. About Us LinkedIn MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions. Twitter 630 Dundee Road Suite 430 Northbrook, IL 60062 USA : 1-888-600-6441 sales@marketsandmarket s.com